Partnering with scientists to accelerate transformation in cancer research

Our Funding Programs
Our Research Portfolio
Our Investments

latest news

Collaboration Launched with Cancer Research Institute to Evaluate Liquid Biopsy

Read More

New Blood Discoveries Grant Program Supported by Novel Three-Way Collaboration

Read More

Liquid Biopsy ASPIRE Awards Announced

Read More

A Note on COVID-19/Novel Coronavirus

Read More

Our Mission

The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and early-stage companies in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding basic and translational cancer research that bridges the gap between bench and bedside through grants and venture investments.


Our Grant Portfolio

100 Grants

Over $90 Million Awarded

  • 43% Translational Science
  • 26% Technology Innovation
  • 23% Basic Research
  • 5% Therapeutic Discovery
  • 3% Clinical

Funding By Cancer Type

  • 47% All cancer types
  • 9% Others
  • 9% Leukemia
  • 8% Brain Tumors
  • 7% Melanoma
  • 6% Breast Cancer
  • 4% Pancreatic Cancer
  • 3% Colorectal Cancer
  • 3% Lung Cancer
  • 2% Lymphoma
  • 1% Ovarian Cancer
  • 1% Prostate Cancer

Over 50 Institutions

In 6 Countries

  • USA